Literature DB >> 6183088

[Endoscopic transpapillary bile duct drainage in malignant obstructive jaundice].

L Safrany, B Schott, S Krause, T Balint, G Portocarrero.   

Abstract

Endoscopic biliary duct drainage was performed in 54 patients with obstructive jaundice caused by papillary carcinoma (n = 4), periampullar carcinoma (n = 4), carcinoma of head of pancreas (n = 16), primary biliary duct carcinoma (n = 14), biliary bladder carcinoma (n = 14) and hilar lymph node metastases (n = 2) using a bilioduodenal endoprosthesis. Drainage was successful in 45 cases; serum bilirubin decreased rapidly, well-being improved, appetite and weight increased. The average survival time was 4.8 months. The initially high rate of complications, mainly due to cholangitis, with a mortality rate of 9.3% could be reduced drastically after use of a duodenoscope with a 3.7 mm bore instrumentation canal enabling insertion of well-draining wide-lumen endoprostheses. Drainage should only be used in non-resectable tumours, general inoperability or for preoperative relief of biliary ducts in jaundice and prospective curative surgical intervention. As results improve with mounting experience it may be expected that endoscopic biliary duct drainage will replace palliative surgery, especially in elderly patients at risk.

Entities:  

Mesh:

Year:  1982        PMID: 6183088     DOI: 10.1055/s-2008-1070222

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  3 in total

1.  Endoscopic retrograde drainage for bile duct cancer.

Authors:  N Soehendra; H Grimm
Journal:  World J Surg       Date:  1988-02       Impact factor: 3.352

2.  [Surgical, endoscopic or radiologic interventional therapy in bile duct cancer].

Authors:  T Böttger; P Perlia; W Weber; T Junginger
Journal:  Langenbecks Arch Chir       Date:  1990

Review 3.  Current Endoscopic Management of Malignant Biliary Stricture.

Authors:  Chi-Chih Wang; Tzu-Wei Yang; Wen-Wei Sung; Ming-Chang Tsai
Journal:  Medicina (Kaunas)       Date:  2020-03-05       Impact factor: 2.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.